BCR-RET · Variant type: fusion · Fusion partner: BCR
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 2 | Selpercatinib | 99.4% | 0.6% | 96.72 |
| 3 | Fedratinib | 99.3% | 0.7% | 96.21 |
| 4 | Lenvatinib | 99.2% | 0.8% | 97.74 |
| 5 | Ponatinib | 99.1% | 0.9% | 78.23 |
| 6 | Regorafenib | 98.9% | 1.1% | 95.99 |
| 7 | Nintedanib | 98.9% | 1.1% | 90.23 |
| 8 | Alectinib | 98.8% | 1.2% | 95.49 |
| 9 | Entrectinib | 98.8% | 1.2% | 93.69 |
| 10 | Alpelisib | 98.6% | 1.4% | 97.22 |
| 11 | Tivozanib | 98.5% | 1.4% | 92.42 |
| 12 | Tenalisib | 97.7% | 2.3% | 97.98 |
| 13 | Brigatinib | 95.8% | 4.2% | 82.96 |
| 14 | Gilteritinib | 95.8% | 4.2% | 88.97 |
| 15 | Sorafenib | 95.5% | 4.5% | 96.72 |
| 16 | Cabozantinib | 94.8% | 5.2% | 92.73 |
| 17 | Futibatinib | 93.7% | 6.3% | 98.48 |
| 18 | Vandetanib | 91.4% | 8.6% | 95.74 |
| 19 | Sunitinib | 90.7% | 9.3% | 91.73 |
| 20 | Avapritinib | 86.4% | 13.6% | 97.73 |
| 21 | Axitinib | 84.9% | 15.1% | 93.23 |
| 22 | Ibrutinib | 78.8% | 21.2% | 94.74 |
| 23 | Fostamatinib | 78.1% | 21.9% | 96.74 |
| 24 | Erdafitinib | 77.2% | 22.8% | 95.71 |
| 25 | Ripretinib | 70.7% | 29.3% | 92.95 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 100.0% | — | — |
| Selpercatinib | 99.4% | — | — |
| Fedratinib | 99.3% | — | — |
| Lenvatinib | 99.2% | — | — |
| Ponatinib | 99.1% | — | — |
| Regorafenib | 98.9% | — | — |
| Nintedanib | 98.9% | — | — |
| Alectinib | 98.8% | — | — |
| Entrectinib | 98.8% | — | — |
| Alpelisib | 98.6% | — | — |
| Tivozanib | 98.5% | — | — |
| Tenalisib | 97.7% | — | — |
| Brigatinib | 95.8% | — | — |
| Gilteritinib | 95.8% | — | — |
| Sorafenib | 95.5% | — | — |
| Cabozantinib | 94.8% | — | — |
| Futibatinib | 93.7% | — | — |
| Vandetanib | 91.4% | — | — |
| Sunitinib | 90.7% | — | — |
| Avapritinib | 86.4% | — | — |
| Axitinib | 84.9% | — | — |
| Ibrutinib | 78.8% | — | — |
| Fostamatinib | 78.1% | — | — |
| Erdafitinib | 77.2% | — | — |
| Ripretinib | 70.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.2ms